

**FEDERAL MARITIME COMMISSION****Notice of Agreement Filed**

The Commission hereby gives notice of the filing of the following agreement under the Shipping Act of 1984. Interested parties may submit comments on the agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within twelve days of the date this notice appears in the **Federal Register**. A copy of the agreement is available through the Commission's Web site ([www.fmc.gov](http://www.fmc.gov)) or by contacting the Office of Agreements at (202)–523–5793 or [tradeanalysis@fmc.gov](mailto:tradeanalysis@fmc.gov).

*Agreement No.:* 011284–077.

*Title:* Ocean Carrier Equipment Management Association Agreement.

*Parties:* Alianca Navegacao e Logistica Ltda.; APL Co. Pte Ltd.; American President Lines, Ltd.; Maersk Line A/S; CMA CGM, S.A.; COSCO Shipping Co., Ltd.; Evergreen Line Joint Service Agreement; Hamburg-Süd; Hapag-Lloyd AG; Hapag-Lloyd USA LLC; Ltd.; Hyundai Merchant Marine Co. Ltd.; Kawasaki Kisen Kaisha, Ltd.; Mediterranean Shipping Company, S.A.; Mitsui O.S.K. Lines Ltd.; Nippon Yusen Kaisha Line; Orient Overseas Container Line Limited; United Arab Shipping Limited; Yang Ming Marine Transport Corp.; and Zim Integrated Shipping Services, Ltd.

*Filing Party:* Jeffrey F. Lawrence, Esq. and Donald J. Kassilke, Esq.; Cozen O'Connor; 1200 Nineteenth Street NW., Washington, DC 20036.

*Synopsis:* The amendment deletes parties to the agreement; revises the affiliations of certain members; and reflects updates to the name and address of a party.

*Agreement No.:* 012206–003.

*Title:* Grimaldi/"K" Line Space Charter Agreement.

*Parties:* Grimaldi Deep Sea S.P.A.; Grimaldi Euromed S.p.A.; and Kawasaki Kisen Kaisha, Ltd.

*Filing Party:* John P. Meade, General Counsel; "K" Line America, Inc.; 6199 Bethlehem Road; Preston, MD 21655.

*Synopsis:* The amendment updates the Agreement to correct clerical errors and expands the geographic scope of the Agreement.

*Agreement No.:* 012486.

*Title:* Crowley/King Ocean Vessel Sharing Agreement.

*Parties:* Crowley Latin America Services, LLC and King Ocean Services Limited, Inc.

*Filing Party:* Wayne Rohde, Esq.; Cozen O'Connor; 1200 Nineteenth Street NW., Washington, DC 20036.

*Synopsis:* The agreement authorizes the parties to share vessels in the trade between Florida on the one hand and Costa Rica and Panama on the other hand.

By Order of the Federal Maritime Commission.

Dated: June 16, 2017.

**Rachel E. Dickon,**

*Assistant Secretary.*

[FR Doc. 2017–12946 Filed 6–20–17; 8:45 am]

**BILLING CODE 6731-AA-P**

**FEDERAL RESERVE SYSTEM****Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company**

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than July 7, 2017.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001:

1. *Erika R. Feingold Irrevocable Insurance Trust dated August 1, 1985, Chad M. Feingold Irrevocable Insurance Trust dated August 1, 1985, Chad M. Feingold Grantor Trust dated August 24, 1998, Erika R. Feingold Grantor Trust, Mark A. Morgan Family Irrevocable Trust dated January 29, 1998, Thomas S. Morgan Family Irrevocable Trust dated January 30, 1998, Mia M. Velasquez Irrevocable Trust dated October 30, 2000, Avi Velasquez Irrevocable Trust dated June 2, 2003, Marley Blake Velasquez Irrevocable Trust dated December 13, 2004, all of Overland Park, Kansas, and Marilyn R. O'Halloran Revocable Trust, Leawood, Kansas, of which Robert J. O'Halloran, Overland Park, Kansas, serves as trustee or co-trustee, and Marilyn R. O'Halloran, individually as co-trustee of the Marilyn R. O'Halloran Revocable Trust;* to retain voting shares and be approved as members of the O'Halloran

control group, which own voting shares of Valley View Bancshares, Inc., Overland Park, Kansas, and indirectly owns Security Bank of Kansas City, Kansas City, Kansas.

Board of Governors of the Federal Reserve System, June 16, 2017.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2017–12930 Filed 6–20–17; 8:45 am]

**BILLING CODE 6210-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention**

[CDC–2017–0028, Docket Number NIOSH–290]

**Draft Current Intelligence Bulletin: The Occupational Exposure Banding Process: Guidance for the Evaluation of Chemical Hazards; Reopening of Comment Period**

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice and reopening of comment period.

**SUMMARY:** On March 15, 2017 the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), published a notice in the **Federal Register** [82 FR 13809] announcing the availability of a draft Current Intelligence Bulletin entitled *The Occupational Exposure Banding Process: Guidance for the Evaluation of Chemical Hazards* for public comment. NIOSH convened a public meeting in Cincinnati, Ohio on Tuesday, May 23, 2017 to discuss the document. The draft document can be found at [www.regulations.gov](http://www.regulations.gov) by entering CDC–2017–0028 in the search field and clicking "Search." Written comments were to be received by June 13, 2017. In response to a request from an interested party, NIOSH is announcing the reopening of the comment period.

**DATES:** Electronic or written comments must be received by July 21, 2017.

**FOR FURTHER INFORMATION CONTACT:** Melissa Seaton, NIOSH, Education and Information Division, 1090 Tusculum Avenue, MS C–32, Cincinnati, OH 45226, telephone (513) 533–8248, Fax (513) 533–8230 (not toll free numbers), email [MSeaton@cdc.gov](mailto:MSeaton@cdc.gov).

**ADDRESSES:** You may submit comments, identified by CDC-2017-0028 and Docket Number NIOSH-290, by either of the following two methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.
- *Mail:* National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, Ohio 45226-1998.

**John Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2017-12942 Filed 6-20-17; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2017-N-2769]

#### Development of New Tuberculosis Treatment Regimens—Scientific and Clinical Trial Design Considerations; Public Workshop; Request for Comments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA, the Agency, or we) is/are announcing a public workshop regarding scientific and clinical trial design considerations for the development of new tuberculosis (TB) treatment regimens. This public workshop is intended to provide information for and gain perspective from health care providers, other U.S. Government Agencies, academic experts, industry, and other stakeholders regarding scientific and clinical trial design considerations related to the development of new TB regimens.

**DATES:** The public workshop will be held on July 19, 2017, from 8:30 a.m. to 5 p.m. Submit either electronic or written comments on this public workshop by August 1, 2017. See the **SUPPLEMENTARY INFORMATION** section for registration date and information. The workshop draft agenda will be made available at <https://www.fda.gov/Drugs/NewsEvents/ucm548365.htm> prior to the meeting.

**ADDRESSES:** The public workshop will be held at FDA's White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993.

Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to <https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm>.

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before August 1, 2017. The <https://www.regulations.gov> electronic filing system will accept comments until midnight eastern time on August 1, 2017. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

#### Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

#### Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for

information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

*Instructions:* All submissions received must include the Docket No. FDA-2017-N-2769 for "Development of New Tuberculosis Treatment Regimens—Scientific and Clinical Trial Design Considerations; Public Workshop; Request for Comments." Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- *Confidential Submissions—*To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

*Docket:* For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Lori Benner and/or Jessica Barnes, Center for